159 related articles for article (PubMed ID: 23035044)
21. Micro RNAs: the future of idiopathic pulmonary fibrosis therapy.
Saco TV; Parthasarathy PT; Cho Y; Lockey R; Kolliputi N
Cell Biochem Biophys; 2015 Jan; 71(1):509-11. PubMed ID: 25164114
[No Abstract] [Full Text] [Related]
22. The promise of epigenetic therapies in treatment of idiopathic pulmonary fibrosis.
Rosas IO; Yang IV
Am J Respir Crit Care Med; 2013 Feb; 187(4):336-8. PubMed ID: 23418324
[No Abstract] [Full Text] [Related]
23. NOX-4 is expressed in thickened pulmonary arteries in idiopathic pulmonary fibrosis.
Pache JC; Carnesecchi S; Deffert C; Donati Y; Herrmann FR; Barazzone-Argiroffo C; Krause KH
Nat Med; 2011 Jan; 17(1):31-2; author reply 32-3. PubMed ID: 21217672
[No Abstract] [Full Text] [Related]
24. Reduced primary cilia length and altered Arl13b expression are associated with deregulated chondrocyte Hedgehog signaling in alkaptonuria.
Thorpe SD; Gambassi S; Thompson CL; Chandrakumar C; Santucci A; Knight MM
J Cell Physiol; 2017 Sep; 232(9):2407-2417. PubMed ID: 28158906
[TBL] [Abstract][Full Text] [Related]
25. Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis.
Wang Y; Yella JK; Ghandikota S; Cherukuri TC; Ediga HH; Madala SK; Jegga AG
Ther Adv Respir Dis; 2020; 14():1753466620971143. PubMed ID: 33167785
[TBL] [Abstract][Full Text] [Related]
26. Suitability of nitisinone for alkaptonuria.
Häberle J
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):732-733. PubMed ID: 32822593
[No Abstract] [Full Text] [Related]
27. Regulation of Collagen V Expression and Epithelial-Mesenchymal Transition by miR-185 and miR-186 during Idiopathic Pulmonary Fibrosis.
Lei GS; Kline HL; Lee CH; Wilkes DS; Zhang C
Am J Pathol; 2016 Sep; 186(9):2310-6. PubMed ID: 27392970
[TBL] [Abstract][Full Text] [Related]
28. Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis.
Kropski JA; Lawson WE; Young LR; Blackwell TS
Dis Model Mech; 2013 Jan; 6(1):9-17. PubMed ID: 23268535
[TBL] [Abstract][Full Text] [Related]
29. Interaction between the promoter
Stock CJ; Conti C; Montero-Fernandez Á; Caramori G; Molyneaux PL; George PM; Kokosi M; Kouranos V; Maher TM; Chua F; Rice A; Denton CP; Nicholson AG; Wells A; Sestini P; Renzoni EA
Thorax; 2020 Oct; 75(10):901-903. PubMed ID: 32580994
[TBL] [Abstract][Full Text] [Related]
30. Network analysis reveals rare disease signatures across multiple levels of biological organization.
Buphamalai P; Kokotovic T; Nagy V; Menche J
Nat Commun; 2021 Nov; 12(1):6306. PubMed ID: 34753928
[TBL] [Abstract][Full Text] [Related]
31. Structural and functional analysis of mutations in alkaptonuria.
Rodríguez JM; Timm DE; Titus GP; Beltrán-Valero De Bernabé D; Criado O; Mueller HA; Rodríguez De Córdoba S; Peñalva MA
Hum Mol Genet; 2000 Sep; 9(15):2341-50. PubMed ID: 11001939
[TBL] [Abstract][Full Text] [Related]
32. Neuroendocrine breast carcinoma: a rare but challenging entity.
Trevisi E; La Salvia A; Daniele L; Brizzi MP; De Rosa G; Scagliotti GV; Di Maio M
Med Oncol; 2020 Jul; 37(8):70. PubMed ID: 32712767
[TBL] [Abstract][Full Text] [Related]
33. Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players.
Samarelli AV; Tonelli R; Marchioni A; Bruzzi G; Gozzi F; Andrisani D; Castaniere I; Manicardi L; Moretti A; Tabbì L; Cerri S; Beghè B; Dominici M; Clini E
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445658
[TBL] [Abstract][Full Text] [Related]
34. Milestones in treatments for inborn errors of metabolism: Reflections on Where chemistry and medicine meet.
Vernon HJ; Manoli I
Am J Med Genet A; 2021 Nov; 185(11):3350-3358. PubMed ID: 34165242
[TBL] [Abstract][Full Text] [Related]
35. Eye of the beholder: Rare eye diseases in focus.
Mohan R
J Neurosci Res; 2019 Jan; 97(1):3-6. PubMed ID: 30444055
[No Abstract] [Full Text] [Related]
36. A rare case of acquired methemoglobinemia associated with alkaptonuria.
Isa Y; Nihei S; Irifukuhama Y; Ikeda T; Matsumoto H; Nagata K; Harayama N; Aibara K; Kamochi M
Intern Med; 2014; 53(16):1797-800. PubMed ID: 25130113
[TBL] [Abstract][Full Text] [Related]
37. Putting the brakes on age-related idiopathic pulmonary fibrosis: can Nox4 inhibitors suppress IPF?
Turn CS; Lockey RF; Kolliputi N
Exp Gerontol; 2015 Mar; 63():81-2. PubMed ID: 25668226
[No Abstract] [Full Text] [Related]
38. Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis.
Barnes JW; Duncan D; Helton S; Hutcheson S; Kurundkar D; Logsdon NJ; Locy M; Garth J; Denson R; Farver C; Vo HT; King G; Kentrup D; Faul C; Kulkarni T; De Andrade JA; Yu Z; Matalon S; Thannickal VJ; Krick S
Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L141-L154. PubMed ID: 31042083
[TBL] [Abstract][Full Text] [Related]
39. The Aging Lung and Idiopathic Pulmonary Fibrosis.
Gulati S; Thannickal VJ
Am J Med Sci; 2019 May; 357(5):384-389. PubMed ID: 31010465
[TBL] [Abstract][Full Text] [Related]
40. Modifying protein misfolding.
Jones D
Nat Rev Drug Discov; 2010 Nov; 9(11):825-7. PubMed ID: 21030987
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
